Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Oct. 03, 2016 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced a partnership with the Hepatitis B Foundation to support the Patient Storytelling Campaign. This campaign is organized to raise awareness about chronic HBV infection, a global medical unmet need, decrease the associated stigma and discrimination, and promote the importance of increased testing and referral to care for HBV.
“We are excited to provide grant funding to the Hepatitis B Foundation to support an initiative focused on raising awareness about chronic HBV infection, a significant unmet medical need and the leading cause of hepatocellular carcinoma (HCC),” said Dr. Mark J. Murray, Arbutus’ President and CEO. “The Hepatitis B Foundation’s Patient Storytelling Campaign focuses on increasing public awareness and promoting patient screening and care, critical factors that are complementary to our mission of curing HBV. We are focused on developing combination treatment regimens and have assembled a broad portfolio of HBV pipeline assets to allow for efficient discovery and development of proprietary drug combinations to increase cure rates.”
“What better way to acknowledge the burden of the world’s most common, serious liver infection than by creating a program to help people affected by hepatitis B share their stories,” said Joan Block, RN, BSN, executive director and co-founder of the Hepatitis B Foundation. “Our goal is to make hepatitis B an urgent public health priority and to raise public understanding about the true impact of this disease on individual lives through personal storytelling.”
About Liver Cancer Awareness Month
October is designated Liver Cancer Awareness Month to increase attention on this deadly cancer. Chronic hepatitis B infection is the leading cause of primary liver cancer, which is the second leading cause of cancer deaths globally. In the United States, liver cancer is one of the only cancers increasing in incidence while most other cancer rates are declining or stabilizing; it is also the second deadliest cancer with a five-year survival rate less than fifteen percent. The prevention and treatment of hepatitis B is essential to decreasing the burden of morbidity and mortality from primary liver cancer.
About the Hepatitis B Foundation
The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection. Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604.419.3200 Email: [email protected] Helia Baradarani Senior Manager, Investor Relations Phone: 604.419.3200 Email: [email protected] Media Please direct all media inquiries to: [email protected]
